Physician profile
Sidney A Rosman
NPI 1366530024
$3,346.31
in general payments reported to CMS, 2019-2025
28 companies · $98.62 in 2025
The $98.62 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $411 · 2021: $602 · 2022: $534 · 2023: $462 · 2024: $310 · 2025: $98.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.01 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $501.07 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $471.52 | 2019-2024 | Skyrizi, Rinvoq |
| Celgene Corporation | $360.50 | 2021-2024 | Zeposia |
| Amgen INC. | $205.72 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.22 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $130.37 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $124.98 | 2020-2022 | |
| Mannkind Corporation | $93.30 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $83.73 | 2023-2025 | Voquezna |
| Dexcom, INC. | $45.46 | 2022 | |
| Redhill Biopharma INC. | $43.73 | 2021-2022 | |
| Ardelyx, INC. | $42.49 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $40.74 | 2019-2021 | |
| Novo Nordisk INC | $38.74 | 2019-2023 | Saxenda, Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.21 | 2024 | Cologuard Collection Kit |
| Celltrion USA INC. | $27.60 | 2025 | Vegzelma |
| Micro-Tech Endoscopy USA, INC. | $24.05 | 2024 | Blueboost, Lesionhunter |
| Ferring Pharmaceuticals INC. | $23.65 | 2019 | |
| Braintree Laboratories, INC. | $20.98 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.67 | 2022 | |
| Alfasigma USA, INC. | $18.33 | 2020 | |
| Shionogi INC | $18.03 | 2019 | |
| Senseonics, Incorporated | $17.00 | 2019 | |
| Madrigal Pharmaceuticals | $15.22 | 2025 | Rezdiffra |
| Allergan, INC. | $14.67 | 2019 | |
| Capsovision, INC. | $13.43 | 2024 | Capsocam Plus |
| Gilead Sciences, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Rosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.